News headlines about Enzon Pharmaceuticals (NASDAQ:ENZN) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Enzon Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.6400703661965 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Enzon Pharmaceuticals (NASDAQ ENZN) traded down 2.0984% on Friday, hitting $0.3779. 54,805 shares of the company’s stock traded hands. The company has a market cap of $16.71 million and a price-to-earnings ratio of 18.8950. Enzon Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $0.50. The firm’s 50-day moving average price is $0.37 and its 200 day moving average price is $0.30.

WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C.

Insider Buying and Selling by Quarter for Enzon Pharmaceuticals (NASDAQ:ENZN)

Receive News & Stock Ratings for Enzon Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.